ABSTRACT
Objective: To investigate the necessity of sub-classification for Barcelona clinic liver cancer (BCLC) classification stage B hepatocellular carcinoma (HCC), and to analyze the curative effect and survival of patients with different substages HCC after TACE. Methods: Clinical and follow-up data of 133 patients with BCLC classification stage B HCC treated with TACE were retrospectively analyzed. There were 31 cases of substage B1, 77 of substage B2, 15 of substage B3 and 10 cases of substage B4. The curative effect and survival of patients were evaluated. Results: Totally 567 times of TACE treatments were performed on 133 patients. There was no statistical difference of the TACE treatment times among patients with different substages (F=1.702, P=0.170). One month after the first time TACE, partial response was achieved in 47 cases, while stable disease and progressive disease were found in 74 cases and 12 cases respectively according to modified response evaluation criteria in solid tumors criteria. No statistical difference of curative effect was detected among patients with different substages (χ2=2.121, P=0.908). The overall survival of patients with different substages HCC after TACE was statistically different (χ2=10.846, P=0.013). The survival time of patients with substage B1 was significantly longer than that of patients with substage B3 (P=0.020) and B4 (P=0.033), respectively. Conclusion: The overall survival of patients with BCLC classification stage B HCC after TACE are different. This sub-classification is beneficial for clinic to formulate specific treatment plan.
ABSTRACT
Objective To investigate the clinical efficacy and safety of the cytokine-induced killer cells (CIK) treated in patients with advanced pancreatic cancer. Methods 74 cases (hospitalized from January 2012 to December 2013) with advanced pancreatic cancer (Ⅲ ~ Ⅳ stage) were selected. The patients were randomly divided into two groups: CIK cells treated group (38 patients) and chemotherapy group (36 cases). Patients in CIK cells group received CIK cell infusion therapy , and patients in chemotherapy group received only gemcitabine. The efficacy and safety of all patients were observed. Results The efficacy rate of CIK cells group was 29.0%, with no statistical significance compared to chemotherapy alone group (16.7%). Disease control rate was 63.2%, with statistical significance compared to the chemotherapy group (38.9%). The PFS was 3 months (95%CI:2.5 ~ 3.5), OS 6.8 months (95%CI:6.1 ~ 7.5). 6-month survival rate 41.7%, with statistically significance compared to chemotherapy group. Conclusion CIK cells treated in patients with advanced pancreatic cancer is feasible and safe , and can improve disease control rate , improve immunity and produce clinical benefit in patients.
ABSTRACT
We describe a 58-years-old man with a primary nasopharyngeal carcinoma accompanying erythroderma. His first symptoms were systemic scattered erythema and itching for six months. Lower right cervical lymphadenectasis was found by physical examination. A neoplasm in nasopharynx could be seen with nasal endoscope. The pathology of the neoplasm was non-keratinizing carcinoma. This case illustrates that "erythroderma" could be a paraneoplastic effect of nasopharyngeal carcinoma.